Ocugen (OCGN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Nov, 2026Executive summary
Special meeting scheduled for Dec. 22, 2026, at 8:00 a.m. ET; attendance is virtual.
Voting deadline is Dec. 21, 2026, at 11:59 p.m. ET.
Voting matters and shareholder proposals
Stockholders may vote on proposals presented at the meeting; proxy materials are available online or by paper or email request through Dec. 8, 2026.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Ocugen
- OCU400’s Q1 2027 readout anchors a broad, late-stage gene-therapy pipeline.OCGN
Stifel 2026 Healthcare Conference 2026 - Board backs a 250 million-share authorization increase for the December 22 vote.OCGNProxy filing
- 2027 pivotal readouts approach amid going-concern and share-conversion risks.OCGNQ3 2026
- The 250 million-share authorization vote was deferred to October 26.OCGNEGM 2026
- Share increase proposal lacked approval; meeting adjourned for further voting on October 5, 2026.OCGNEGM 2026
- Late-stage gene therapies for major eye diseases advance toward BLA filings, with cash runway into 2028.OCGNH.C. Wainwright 28th Annual Global Investment Conference
- Shareholders will vote to increase authorized shares to support growth and commercialization.OCGNProxy filing
- Pivotal gene therapy trials for RP and Stargardt aim for global launches by 2028.OCGNCanaccord Genuity's 46th Annual Growth Conference
- FDA cleared OCU410 phase III; $130M financing extends cash runway to 2028 amid going concern risk.OCGNQ2 2026